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Abstract
Heavy training is associated with increased respiratory infection risk and antimicrobial proteins are important in defence
against oral and respiratory tract infections. We examined the effect of 14 weeks of vitamin D3 supplementation (5000 IU/
day) on the resting plasma cathelicidin concentration and the salivary secretion rates of secretory immunoglobulin A (SIgA),
cathelicidin, lactoferrin and lysozyme in athletes during a winter training period. Blood and saliva were obtained at the start
of the study from 39 healthy men who were randomly allocated to vitamin D3 supplement or placebo. Blood samples were
also collected at the end of the study; saliva samples were collected after 7 and 14 weeks. Plasma total 25(OH)D
concentration increased by 130% in the vitamin D3 group and decreased by 43% in the placebo group (both P = 0.001).
The percentage change of plasma cathelicidin concentration in the vitamin D3 group was higher than in the placebo group
(P = 0.025). Only in the vitamin D3 group, the saliva SIgA and cathelicidin secretion rates increased over time (both
P = 0.03). A daily 5000 IU vitamin D3 supplement has a beneﬁcial effect in up-regulating the expression of SIgA and
cathelicidin in athletes during a winter training period, which could improve resistance to respiratory infections.
Keywords: cholecalciferol, SIgA, cathelicidin, salivary ﬂow rate
Introduction
Vitamin D can be obtained either from dietary
sources or from the epidermal layer of the skin via
exposure to sunlight. Two forms of vitamin D can be
obtained from dietary sources: vitamin D3 (cholecal-
ciferol) and vitamin D2 (ergocalciferol). While vita-
min D3 is found in food from animal origin, such as
cod-liver oil, salmon and egg yolk, vitamin D2 is
present in some plants and fungi. The vitamin D3
production from ultraviolet-mediated conversion of
7-dehydrocholesterol in the plasma membrane of
skin cells provides 80–100% of the body's require-
ments (Lanteri, Lombardi, Colombini, & Banﬁ,
2013). The endogenously synthesised vitamin D3
and diet-derived D2 and D3 must ﬁrst be hydroxy-
lated in the liver into 25-hydroxy vitamin D (25(OH)
D), the main storage form. In the second hydroxyla-
tion, 25(OH)D is converted to the biologically active
form, 1,25-dihydroxy vitamin D, by 1-α-hydroxylase
in the kidney or some cells in non-renal
compartments, such as cells of the immune system
including T cells, B cells, macrophages and dendritic
cells (Aranow, 2011).
It has recently been recognised that vitamin D is a
vital mediator of innate immune responses, enhan-
cing the antimicrobial properties of immune cells
such as monocytes and macrophages (Bikle, 2009).
Vitamin D is a key link between Toll-like receptor
activation and antimicrobial responses in innate
immunity. Following activation of the Toll-like
receptor signalling cascade in the presence of
microbes, vitamin D has a vital role in up-regulating
the production of antimicrobial proteins (AMPs),
such as cathelicidin and β-defensin (Liu et al.,
2006). The biologically active 1,25-dihydroxy vita-
min D binds to vitamin D receptors and induces
expression of vitamin D-responsive genes to enhance
the production of cathelicidin and β-defensin (Wang
et al., 2004). These AMPs have a broad range of
activities against microorganisms and may be
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involved in the direct inactivation of viruses through
membrane destabilisation (Kamen & Tangpricha,
2010). They are produced by epithelial cells and
macrophages and in the lungs are secreted into the
bioﬁlm covering the inner surface of the airways,
thereby creating a barrier that is chemically lethal
to microbes. Recently, we demonstrated that vitamin
D status inﬂuences the resting plasma cathelicidin
concentration and salivary SIgA secretion rate in
endurance athletes during a winter training period
(He et al., 2013). The plasma cathelicidin concen-
tration in athletes with high-level vitamin D status
(plasma 25(OH)D > 90 nmol/L) was signiﬁcantly
higher than in athletes with low-level vitamin D sta-
tus (<33 nmol/L) and there was a positive correla-
tion between the plasma 25(OH)D and cathelicidin
concentrations. In addition, the averaged SIgA
secretion rate during the 4-month winter period in
the individuals who had relatively high vitamin D
status (plasma 25(OH)D > 120 nmol/L) was signiﬁ-
cantly higher than in groups having adequate, inade-
quate and deﬁcient vitamin D status (adequate:
50– 99.9 nmol/L; inadequate: 30–49.9 nmol/L; deﬁ-
cient: <30 nmol/L) as previously established for
bone health.
Vitamin D insufﬁciency has been reported to be
common in athletes in the United Kingdom (UK),
especially when training in the winter months (Close
et al., 2013; He et al., 2013; Morton et al., 2012).
Two studies that assessed the vitamin D status of
UK-based professional athletes (latitude 53°N)
reported that 62% of athletes (38/61) including pro-
fessional rugby players, soccer players and jockeys
had inadequate serum total 25(OH)D concentra-
tions (<50 nmol/L) in the winter months (Close
et al., 2013) and 65% of elite soccer players in the
English Premier League (13/20) presented with
serum total 25(OH)D concentrations <50 nmol/L
in December (Morton et al., 2012). In our previous
study on a large student cohort of endurance ath-
letes, we also found that 55% of endurance athletes
(100/181) had serum total 25(OH)D concentrations
<50 nmol/L at the end of the 4-month winter train-
ing period (He et al., 2013). Given the high preva-
lence of insufﬁcient vitamin D status in athletes in
the UK during winter months, it seems probable that
vitamin D supplementation could be desirable for
athletes during this period to increase vitamin D
concentrations to up-regulate the expression of
AMPs and possibly reduce the risk of respiratory
infections.
The purpose of this study was to examine the
effect of 14 weeks of vitamin D3 supplementation
(5000 IU/day) on the resting plasma cathelicidin
concentration and the salivary concentrations and
secretion rates of SIgA, cathelicidin, lactoferrin
and lysozyme in a population of individuals
engaged in regular sport training during a winter
training period.
Methods
Participants
Fifty healthy men aged 20.4 ± 1.9 years who were
engaged in regular sports training (such as rugby,
volleyball, swimming, triathlon, cycling and racquet
sports) from Loughborough University, UK (latitude
53°N), volunteered to participate in the study during
November 2013 and their self-reported training
loads (determined by a pre-screening questionnaire)
averaged 11 ± 4 h/week (mean ± s). Participants
were required to complete a comprehensive health-
screening questionnaire prior to starting the study
and had not taken any regular medication or anti-
biotics in the 3 months prior to the study. All parti-
cipants were fully informed about the rationale for
the study and of all experimental procedures to be
undertaken. Participants provided written consent to
participate in the study, which had earlier received
the approval of Loughborough University ethical
advisory committee. Participants were enrolled after
having fulﬁlled all inclusion criteria, and presenting
none of the exclusion criteria (determined by ques-
tionnaire). Participants could be included if they
were currently healthy (with no health problems or
infection symptoms within the previous two weeks),
engaged in regular sports training at least three ses-
sions and at least 3 h of total moderate/high-intensity
training time per week and were between 18–35 years
of age. Participants representing one or more of the
following criteria were excluded from participation:
smoking or use of any medication, suffering from or
had a history of cardiac, hepatic, renal, pulmonary,
neurological, gastrointestinal, haematological or psy-
chiatric illness. Participants were not allowed to take
any other supplements, other than a daily multivita-
min tablet providing no more than the
Recommended Dietary Allowances of essential
vitamins.
Study protocol
Information about the study was given to the parti-
cipants 1–2 weeks before their ﬁrst visit to the
laboratory. For the ﬁrst visit to the laboratory, parti-
cipants arrived in the morning at 09:00–12:00 fol-
lowing a 3-h fast and their body mass and stature
were recorded. Participants were required to abstain
from any strenuous physical activity for 24 h before
coming to the laboratory. Participants sat quietly for
10 min and completed a health-screening question-
naire and inclusion/exclusion criteria questionnaire
before signing an informed consent form and
2 C.-S. He et al.
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providing an unstimulated saliva sample by passive
dribble into a pre-weighed sterile collection tube for
a timed period (usually 2 min; longer was allowed if
the volume of saliva collected after 2 min was insuf-
ﬁcient). After centrifugation for 2 min at 5000 g to
remove cells and insoluble matter, saliva samples
were stored frozen at −20ºC prior to analysis.
Subsequently, a resting venous blood sample (6 ml)
was obtained by venepuncture from an antecubital
forearm vein into a vacutainer tube (Becton
Dickinson, Oxford, UK) containing K3EDTA and
haematological analysis was immediately carried out
(including haemoglobin, haematocrit and total and
differential leukocyte counts) using an automated
cell-counter (Ac.T™5diff haematology analyser,
Beckman Coulter, High Wycombe, UK).
Participants had to have haematology variables
within the normal reference range to be included in
the study. The remaining EDTA blood was centri-
fuged for 10 min at 1500 g and 4°C and the plasma
stored at –20°C prior to analysis.
The participants were randomly allocated to an
intervention (vitamin D3 supplement) group or pla-
cebo group for 14 weeks in a double-blind fashion.
The vitamin D3 group received a daily supplement
of 5000 IU of vitamin D3 in capsule form, whereas
the placebo group received a visually identical cellu-
lose placebo capsule (Bio-Tech Pharmacal,
Arkansas, USA). Participants were given a seven-
week supply of vitamin D3 or placebo capsules and
attended the laboratory again after seven weeks to
get another seven-week supply of supplement.
Participants were also asked to ﬁll in a standard short
form of International Physical Activity Questionnaire
(IPAQ; http://www.ipaq.ki.se/downloads.htm) at
weekly intervals, thus providing the quantitative infor-
mation on training loads in metabolic equivalents
(MET)-h/week (Craig et al., 2003).
Participants attended the laboratory after 7 and 14
weeks following a 3-h fast and their body mass was
recorded again. Participants were also required to
abstain from any strenuous physical activity for
24 h before coming to the laboratory. Blood samples
were collected again at the end of the study and
unstimulated saliva samples were collected after 7
and 14 weeks. A total of 39 participants completed
the study and provided sufﬁcient blood for routine
haematology and vitamin D status analysis at the
start and end of the study and sufﬁcient saliva
(1 mL) for analysis of AMPs on all three occasions.
Plasma analysis
Plasma samples were analysed for total 25(OH)D
and cathelicidin concentrations. Total 25(OH)D
(the sum of the 25-hydroxy metabolites of D2 and
D3) in EDTA plasma was determined after a
maximum of eight months in storage (with no pre-
vious freeze-thaw cycles) using a high-pressure
liquid chromatography–tandem mass spectrometer
(Waters Acuity, Manchester, UK) as described by
Owens et al. (2014) and recommended by Fraser
and Milan (2013) and Wallace, Gibson, De La
Hunty, Lamberg-Allardt, and Ashwell (2010).
Measurements were performed in a laboratory meet-
ing the performance target set by the Vitamin D
External Quality Assessment Scheme Advisory
Panel for 25(OH)D assays.
EDTA plasma with 20X dilution was assayed in
duplicate for cathelicidin concentration using a com-
mercially available ELISA kit (Hycult Biotech,
Uden, The Netherlands) according to the manufac-
turers’ instructions. The intra-assay CV was ± 2.4%
across a working range of 0.1–100 μg/L.
Saliva analysis
Saliva samples were analysed in duplicate for the
salivary AMPs. The saliva volume collected was esti-
mated by weighing and the saliva ﬂow rate was cal-
culated. Saliva samples with 5X dilution were
analysed for SIgA using an ELISA kit (Salimetrics,
Philadelphia, USA). Salivary lactoferrin and lyso-
zyme were analysed using commercially available
ELISA kits (Calbiochem, USA, and Biomedical
Technologies, USA, respectively) with 500X dilu-
tion. Saliva samples were also assayed for cathelici-
din concentration using a commercially available
ELISA kit (Hycult Biotech, Uden, The
Netherlands). Secretion rates for each of the salivary
AMPs were calculated as the multiple of the saliva
ﬂow rate and AMP concentration. All saliva assays
were carried out in duplicate. The intra-assay CVs
for all the assays were < 4% across a working range
of 2.5–600 mg/L for SIgA, 1.6–100 μg/L for lacto-
ferrin, 0.78–50 μg/L for lysozyme and 0.1–100 μg/L
for cathelicidin.
Statistical analysis
The Shapiro–Wilk test was used to determine
whether data sets were normally distributed.
Anthropometric, self-reported training load (h/
week), average IPAQ scores (MET-h/week) and
haematological variables were compared between
the vitamin D3 and placebo groups using unpaired
t-tests for normally distributed data or nonpara-
metric Mann–Whitney U test for non-normally
distributed data. Plasma total 25(OH)D and cathe-
licidin concentrations at the start and end of the
study were assessed between the vitamin D3 and
placebo groups using nonparametric Wilcoxon
signed ranks test and Mann–Whitney U test. The
percentage change of plasma cathelicidin
Vitamin D3 supplement and antimicrobial proteins 3
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concentration during the study period was also
compared between two groups using nonpara-
metric Mann–Whitney U test. The changes in the
concentrations and secretion rates of salivary
AMPs as well as the salivary ﬂow rates over the
14 weeks of the study in the vitamin D3 and pla-
cebo groups were assessed by two-way ANOVA or
nonparametric Friedman tests with post hoc
Dunn's test and Mann–Whitney U test. Data are
presented as mean (± s) for data sets that were
normally distributed; for data sets that were not
normally distributed, the median and interquartile
ranges are shown. The accepted level of signiﬁ-
cance was P < 0.05. Where appropriate, effect
sizes were calculated using Cohen’s d (G*Power
Version 3.1).
Results
Adherence to the study
Thirty-nine participants (vitamin D3: n = 20; pla-
cebo: n = 19) completed the study and provided
sufﬁcient blood for routine haematology and analysis
of 25(OH)D and cathelicidin concentrations on two
occasions and sufﬁcient saliva for analysis of AMPs
on all three occasions. Reasons for dropout were
given as foreign travel (N = 3), injury (N = 6) or
due to undisclosed reasons (N = 2).
Baseline characteristics and physical activity levels
There were no signiﬁcant differences in baseline
anthropometrics or haematological variables
between the vitamin D3 and placebo groups
(Table I). Analysis of the IPAQ questionnaires indi-
cated that the weekly training loads during the study
period were relatively stable within the vitamin D3
and placebo groups. The training loads averaged
over the study period were not signiﬁcantly different
between the vitamin D3 and placebo groups
(Table I). Median (interquartile range) training
loads were 69.0 (49.3–80.3) MET-h/week in the
vitamin D3 group, which is equivalent to about
11.4 h of moderate-vigorous activity per week, and
78.2 (47.6–112.0) MET-h/week in the placebo
group, which is equivalent to about 12.9 h of mod-
erate-vigorous activity per week.
Plasma total 25(OH)D and cathelicidin concentrations
The median plasma total 25(OH)D concentration
increased from 54.5 to 125.5 nmol/L at week 14 in
the vitamin D3 group (P = 0.001, effect size = 2.71)
and decreased from 57.0 to 32.5 nmol/L in the
placebo group at 14 weeks (P = 0.001, effect
size = 0.95) (Table II). At the end of the study
there was a signiﬁcant difference between groups
(P < 0.001, effect size = 4.05). Although the median
Table I. Anthropometric, training and haematological variables in the vitamin D3 and placebo groups at
baseline and their training loads determined by IPAQ during the intervention period.
Vitamin D3 (n = 20) Placebo (n = 19) P
Age (years) 20.1 ± 1.7 1.0 ± 2.3 0.168
Stature (cm) 181.9 ± 6.9 182.2 ± 8.0 0.907
Body mass (kg) 80.8 ± 13.1 80.0 ± 11.2 0.849
BMI (kg/m2) 24.3 ± 3.1 24.1 ± 2.6 0.769
Previous training load (h/week) 10.1 ± 4.0 11.1 ± 4.8 0.503
IPAQ (MET-h/week) 69.0 (49.3–80.3) 78.2 (47.6–112.0) 0.374
RBC count (×1012/L) 4.8 ± 0.3 4.9 ± 0.3 0.231
Haematocrit (%) 44.1 ± 1.9 43.8 ± 2.5 0.687
Haemoglobin (g/L) 148 ± 7 146 ± 7 0.546
Leukocyte count (×109/L) 5.5 ± 1.4 5.7 ± 1.2 0.707
Notes: Data are shown as the mean ± s or the median and interquartile range as appropriate. P values are
from unpaired t-tests apart from IPAQ training load where the Mann–Whitney U test for nonparametric
data was used.
Table II. Plasma total 25(OH)D and cathelicidin concentrations in the vitamin D3 and placebo groups before and after the 14-week
intervention period.
Pre Post P
Total 25(OH)D (nmol/L) Vitamin D3 54.5 (43.2–71.0) 125.5 (96.8–149.5)* 0.001
Placebo 57.0 (38.7–71.0) 32.5 (26.7–49.3) 0.001
Cathelicidin (μg/L) Vitamin D3 29.5 (26.6–32.3) 34.0 (30.0–38.3) 0.003
Placebo 30.9 (27.7–36.6) 33.6 (28.4–38.1) 0.048
Note: Data are shown as the median and interquartile range for nonparametric Wilcoxon signed ranks test. Signiﬁcant difference between
groups: *P < 0.001 based on Mann–Whitney U test.
4 C.-S. He et al.
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plasma cathelicidin concentration increased in both
groups (vitamin D3: 29.5 to 34.0 ng/mL, P = 0.003,
effect size = 0.27; placebo: 30.9 to 33.6 ng/mL,
P = 0.048, effect size = 0.16; Wilcoxon signed
ranks test) (Table II), the percentage change of
cathelicidin concentration in the vitamin D3 group
was higher than in the placebo group (vitamin D3:
15.0%; placebo: 5.4%, P = 0.025, effect size = 0.75;
Mann–Whitney U test) (Figure 1).
Salivary variables
While the concentrations of all salivary AMPs were
not signiﬁcantly altered over time in both vitamin D3
and placebo groups, the salivary ﬂow rates increased
over time in the vitamin D3 group (P = 0.022, effect
size = 0.32) (Table III). The resting SIgA and cathe-
licidin secretion rates increased over time in the
vitamin D3 group (but not in the placebo group)
(SIgA: 58.8, 87.2, 70.5 μg/min, P = 0.026, effect
size = 0.32; cathelicidin: 0.076, 0.103, 0.090 ng/
min, P = 0.030, effect size = 0.21; Friedman tests)
(Figure 2a and b). Salivary lysozyme secretion rate
increased over time in both groups (time, P = 0.002;
two-way ANOVA) but lactoferrin secretion rate was
unaltered (Figure 2c and d).
Discussion
As expected, plasma total 25(OH)D concentration
signiﬁcantly increased in the vitamin D3 group and
signiﬁcantly decreased in the placebo group. The
salivary SIgA and cathelicidin secretion rates signiﬁ-
cantly increased over time in the vitamin D3 group
but not in the placebo group. In addition, the per-
centage change of plasma cathelicidin concentration
in the vitamin D3 group was signiﬁcantly higher than
in the placebo group although plasma cathelicidin
concentration signiﬁcantly increased in both groups.
We demonstrated that in athletes following 14
weeks of vitamin D3 supplementation with 5000
IU/day there was a signiﬁcant increase in the plasma
total 25(OH)D concentration from 54.5 to
125.5 nmol/L. This increase in total 25(OH)D is
similar to a previous randomised placebo-controlled
trial of 5000 IU daily vitamin D3 supplementation,
where plasma 25(OH)D levels increased signiﬁcantly
from 29 to 103 nmol/L in the intervention group
after eight weeks of supplementation (Close et al.,
2013). During the winter months, 5000 IU of vita-
min D3 supplement daily is a possible way for ath-
letes to elevate 25(OH)D concentrations above a
mean of 100 nmol/L, which some authors suggest
is the optimal concentration for a number of bene-
ﬁcial effects (Heaney, 2011; Zittermann, 2003). It
was also observed that plasma total 25(OH)D con-
centration signiﬁcantly decreased in the placebo
Table III. Salivary ﬂow rate and AMPs concentration in the vitamin D3 and placebo groups before and after 7 and 14 weeks of the
intervention.
Week 0 Week 7 Week 14 P
Saliva ﬂow rate (μL/min) Vitamin D3 317 (181–420) 462 (254–642)* 358 (274–640)* 0.022
Placebo 260 (192–496) 331 (242–540) 352 (251–532) 0.143
SIgA concentration (mg/L) Vitamin D3 183.8 (142.0–221.8) 170.3 (121.3–235.8) 171.1 (145.6–217.2) 0.861
Placebo 181.3 (130.4–227.0) 141.4 (120.0–249.9) 171.9 (105.5–245.0) 0.211
Lactoferrin concentration (μg/L) Vitamin D3 4715 (2875–5861) 5358 (2995–7596) 4485 (2342–6810) 0.350
Placebo 4274 (1483–5450) 3772 (1763–5087) 5874 (1235–7550) 0.692
Lysozyme concentration (μg/L) Vitamin D3 2472 ± 2515 2986 ± 2907 2397 ± 1644 time*group, 0.460
Placebo 3367 ± 3135 3205 ± 2500 3018 ± 2389
Cathelicidin concentration (μg/L) Vitamin D3 0.22 (0.09–0.53) 0.32 (0.13–0.45) 0.23 (0.09–0.45) 0.463
Placebo 0.25 (0.05–0.94) 0.16 (0.07–0.37) 0.20 (0.07–0.28) 0.065
Notes: Data are shown as the mean ± s for two-way ANOVA or the median and interquartile range for the nonparametric Friedman test with
post hoc Dunn’s test. The location of signiﬁcant differences from week 0 within the group is indicated as follows: *P < 0.05 (Dunn’s post
hoc test applied when Friedman test P < 0.05).
Figure 1. The percentage change of plasma cathelicidin concen-
tration after the 14-week intervention period in the vitamin D3
supplement and placebo groups. Data are median and interquar-
tile range. *Signiﬁcant difference between groups (P = 0.025;
Mann–Whitney U test).
Vitamin D3 supplement and antimicrobial proteins 5
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group from November to February, probably reﬂect-
ing seasonal changes and time from last effective
ultraviolet exposure. Several other studies that
assessed the plasma 25 (OH)D concentrations of
UK-based athletes have shown that there was no
change or a signiﬁcant decrease in the plasma
25(OH)D levels during the winter training period in
athletes without vitamin D supplementation (Close
et al., 2013; He et al., 2013; Owens et al., 2014). This
is most likely due to insufﬁcient ultraviolet radiation
of appropriate wavelength (290–315 nm) between
November and March in the UK to produce vitamin
D in the skin (Webb & Holick, 1988).
In the present study the resting salivary SIgA and
cathelicidin secretion rates signiﬁcantly increased
over time in the vitamin D3 group. To our knowl-
edge, this is the ﬁrst report to show a signiﬁcant
increase in the resting salivary SIgA secretion rates
after a period of vitamin D3 supplementation. The
reasons for this are still unclear, but could be related
to the elevated salivary ﬂow rates after vitamin D3
supplementation. We report that the salivary ﬂow
rates signiﬁcantly increased over time in the vitamin
D3 group. Several animal studies have demonstrated
that vitamin D receptors are present in the parotid,
submandibular and sublingual salivary glands, which
suggest a possible role for vitamin D in the
regulation of salivary secretion. This is supported
by the ﬁnding that salivary ﬂow rates were stimulated
after treatment with vitamin D3 in vitamin D-deﬁ-
cient rats (Peterfy, Tenenhouse, & Yu, 1988;
Stumpf, 2008). Although the inﬂuence of vitamin
D on salivary ﬂow rate has not yet been demon-
strated in humans, the ﬁnding that there was a sig-
niﬁcant positive correlation between plasma total
25(OH)D concentration and salivary ﬂow rate in
the endurance athlete cohort (N = 225) (unpub-
lished data in our previous study (He et al., 2013),
r = 0.196, P = 0.003; Pearson correlation test) might
lend some support to this suggestion.
We also found that salivary cathelicidin secretion
rates only signiﬁcantly increased in the participants
with vitaminD3 supplementation. Human cathelicidin
is expressed in neutrophils, epithelial cells and salivary
glands and can be detected in whole saliva (Davison,
Allgrove, & Gleeson, 2009; Murakami, Ohtake,
Dorschner, & Gallo, 2002). The elevated salivary
cathelicidin secretion rates might be due to the inﬂu-
ence of 25(OH)D in the human oral epithelial cells.
Human oral epithelial cells, which express vitamin D
receptors and 1-α-hydroxylase, have the enzymatic
machinery to convert 25(OH)D to 1,25-dihydroxy
vitamin D and it has been demonstrated that 25(OH)
D can induce expression of the vitamin D-responsive
Figure 2. Changes in salivary secretion rates after 7 and 14 weeks of the intervention period in the vitamin D3 supplement and placebo
groups for (A) SIgA, (B) cathelicidin, (C) lysozyme and (D) lactoferrin. Data are shown as the mean ± s (lysozyme) or the median and
interquartile range (SIgA, cathelicidin and lactoferrin) as appropriate.
The location of signiﬁcant differences from week 0 within the vitamin D3-supplemented group only is indicated as follows: *P < 0.05;
†P = 0.05 (Dunn’s post hoc test applied when Friedman test P < 0.05). Signiﬁcant difference from week 0 in both groups is indicated as
follows: #P < 0.05.
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genes to enhance the production of cathelicidin by
binding to vitamin D receptors in a dose-related man-
ner in human oral keratinocytes (Wang et al., 2013).
Our results indicate that 5000 IU of vitamin D3
supplement daily could have a beneﬁcial effect in up-
regulating plasma cathelicidin. We found that the
percentage change of cathelicidin concentration in
the vitamin D3 group was signiﬁcantly higher than
in the placebo group, although plasma cathelicidin
concentration signiﬁcantly increased in both groups
from November to March. The reason for the
increase of plasma cathelicidin concentration in the
placebo group is unclear, but could be related to the
likely higher respiratory infection incidence over the
winter months as cathelicidin production is
increased following pathogen exposure and Toll-
like receptor activation (Bucki, Leszczyńska,
Namiot, & Sokołowski, 2010). Moreover, there was
a similar result in another vitamin D3 supplement
study in which 25 healthy participants with plasma
25(OH)D concentration less than 80 nmol/L
ingested 50,000 IU vitamin D3 every other day, for
ﬁve days, and a statistically signiﬁcant increase of
circulating cathelicidin concentration was only
found in participants with 25(OH)D levels increas-
ing more than 80 nmol/L after the vitamin D3 treat-
ment (Bhan et al., 2011). In our study, we also
found a signiﬁcant increase of plasma cathelicidin
concentration in the vitamin D3 group although
there were only ﬁve participants with 25(OH)D
levels increasing more than 80 nmol/L after supple-
mentation. It has been reported that patients with
the lowest circulating concentrations of cathelicidin
undergoing dialysis are at a greater than two-fold
increased risk of death from infectious causes
(Gombart et al., 2009). Given the observed associa-
tions of circulating cathelicidin concentrations and
infection-associated mortality in human studies, a
high dose of vitamin D3 supplementation might be
clinically useful in the populations that may be more
at risk of infection due to occupational or lifestyle
stress (e.g. athletes and military personnel).
Recently, it has been suggested that several sali-
vary AMPs, such as SIgA and cathelicidin, might be
associated with the incidence of upper respiratory
tract infection. Previous studies have shown an
inverse relationship between SIgA values and upper
respiratory tract infection prevalence and low SIgA
values have been reported to be associated with
increased incidence of upper respiratory tract infec-
tion in athletes (Fahlman & Engels, 2005, 2012;
Gleeson et al., 1999; Neville, Gleeson, & Folland,
2008). A one-year follow-up study has reported that
the number of upper respiratory tract infection epi-
sodes was negatively correlated with salivary cathe-
licidin levels (Usui et al., 2012). Further studies are
still needed to establish whether the enhancement of
salivary SIgA and cathelicidin secretion after vitamin
D supplementation could reduce the risk of upper
respiratory tract infection in athletes.
In conclusion, 5000 IU of vitamin D3 supplemen-
tation daily appears to have a beneﬁcial effect in up-
regulating the expression of SIgA and cathelicidin in
athletes during a winter training period. Vitamin D
supplementation, therefore, could have a positive
effect on immune function and lead to decreased
incidence of respiratory infections. Further research
in a substantially larger athlete cohort is needed to
determine this possibility.
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